



# Nebivolol Hydrochloride-Amino Acid Zwitterionic Cocrytals with Superior Physicochemical Characteristics

Chinna Devi<sup>1,2</sup>, Anu Sukhdev<sup>1,3\*</sup>, Deepthi<sup>3,4</sup>, Mohan Kumar<sup>3,4</sup>, Saravanan Chandrasekaran<sup>1</sup>

<sup>1</sup>Department of Chemistry, Presidency University, Bengaluru, Karnataka, India.

<sup>2</sup>Department of Chemistry, MES College of Arts, Commerce and Science, Bengaluru, Karnataka, India.

<sup>3</sup>Material Research Centre, Presidency University, Bengaluru, Karnataka, India.

<sup>4</sup>Department of Physics, Presidency University, Bengaluru, Karnataka, India.

## ABSTRACT

Cocrystallization of drugs with coformers is a promising method for modifying drug substance solid state qualities such as solubility and dissolution. The current study aimed to create, synthesize, and analyze Nebivolol hydrochloride cocrytals by screening several coformers. The type II biopharmaceutical medication Nebivolol hydrochloride (NBH), used to treat hypertension, has great permeability, limited water solubility, and a slow dissolving rate. This remains a barrier to the creation of innovative formulations. In this paper, we focus on the formation of the first NBH zwitterionic cocrytals while using less hazardous zwitterionic amino acids as coformers, such as L-proline (P) and L-glutamine (G). The zwitterionic cocrytals of NBH were synthesized using liquid-aided grinding and slow solvent evaporation procedures by using a molar ratio (1:1) of the drug and zwitterion coformers. The cocrytals revealed a distinctive characteristic in X-ray diffraction studies, FT-IR spectra, SEM images, and DSC thermograms. The infrared study demonstrated the displacement of NBH distinctive bands. The X-Ray Powder Diffraction pattern indicated co-crystallinity and a significant difference in the  $2\theta$  value of intense peaks. Differential scanning calorimetry (DSC) spectra of cocrytals revealed changed endotherms correlating to melting point. Dissolution studies revealed that the zwitterionic NBH cocrytals disintegrated faster in vitro by 89.3% and 84.7%, respectively.

**Key Words:** Pharmaceutical cocrytals, Nebivolol hydrochloride, L-proline, L-glutamine, Solubility and dissolution studies

eIJPPR 2023; 13(5):53-61

**HOW TO CITE THIS ARTICLE:** Devi Ch, Sukhdev A, Deepthi, Kumar M, Chandrasekaran S. Nebivolol Hydrochloride-Amino Acid Zwitterionic Cocrytals with Superior Physicochemical Characteristics. Int J Pharm Phytopharmacol Res. 2023;13(5):53-61. <https://doi.org/10.51847/jFn8PSiLcm>

## INTRODUCTION

In recent years, drug cocrytal design has rapidly progressed from absolute obscurity to an extensively researched category of crystal formations in the field of crystal engineering and science. They considerably increase the variety of active pharmaceutical ingredients (API) crystal forms and allow for improvements in physicochemical characteristics like solubility, dissolution rates, stability, hygroscopicity, and bioavailability that are relevant for clinical use. It is

important to emphasize that in the pharmaceutical cocrytallization approach, cocrytals comprise a multicomponent system of active pharmaceutical ingredients (API) with a stoichiometric amount of a pharmaceutically acceptable conformer incorporated in the crystal lattice, without altering the pharmacological activity of the drug. Cocrytal is formed between API molecules or ions having donor or acceptor moieties that are capable of forming supramolecular synthon through non-covalent interactions between the molecules,  $\pi$ - $\pi$  interactions, and hydrogen bonds with the generally

**Corresponding author:** Anu Sukhdev

**Address:** Department of Chemistry, Presidency University, Bengaluru, Karnataka, India.

**E-mail:** [anusukhdev@yahoo.co.in](mailto:anusukhdev@yahoo.co.in)

**Received:** 20 May 2023; **Revised:** 09 October 2023; **Accepted:** 10 October 2023

This is an **open access** journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.



recognized as safe (GRAS) cofomers having functional groups [1, 2]. There are several ways to make cocrystals, including slow evaporation at ambient temperature [3, 4] reaction cocrystallization [5], cooling co-crystallization [6], the grinding process [7], and supercritical fluid approach [8]. In addition to these techniques, novel techniques including hot-stage microscopy and approaches with ultrasound assistance are also documented [9]. It was evident from both conventional and new approaches that the grinding technique with a few modifications, such as the inclusion of a tiny quantity of solvent (LAG), and solvent evaporation at normal temperature, is better suited for the formation of cocrystals.

The long-acting  $\alpha$ -blocker nebivolol hydrochloride is used to treat hypertension. Owing to its limited solubility in water (0.0091 grams /10 Cm<sup>3</sup>) and dissolving rate, it has a lower bioavailability (11%). The main objective of the current work is the potential for creating cocrystals using cofomers to enhance the solubility and dissolution rate [10]. In the current work, an eco-friendly pharmaceutical cocrystallization process a "green method" adopting solvent-free procedures or minimal use of solvents is used to synthesize Nebivolol cocrystals. Researchers have also been searching for lower-risk amino acids to act as the secure cofomer that results in the required API physicochemical features. In terms of structure, amino acids, particularly L-proline and L-glutamine (which improve API solubility and gastrointestinal absorption) are promising cofomer candidates because they have zwitterionic moieties, which facilitate strong acquaintances, and functional groups that can generate hydrogen bonds that improve stability [11]. Nebivolol hydrochloride structure, which is already in salt form and is electrically neutral by nature, satisfies all the requirements for the successful creation of cocrystals. In the structure, it exhibits successful donor and acceptor protonation, which aids in the creation of non-covalent interaction between the drug and the cofomer.

In the current study, the production of the first NBH zwitterionic cocrystals under the oversight of the cocrystal technology idea may be of interest using amino acids, which are natural zwitterions under physiological preferences. Because the penta cyclic ring "side chain" reduces the molecular structure restricted and rigid, proline appears to be prevalent in cocrystal formation [12].

To emphasize the role of the first NBH zwitterionic cocrystal in enhancing the physicochemical properties of NBH and to demonstrate the significance of the zwitterionic cocrystal in the pharmaceutical field, L-proline and L-glutamine were selected as the cofomer for the reasons listed below. From a structural standpoint, L-proline and L-glutamine possess all characteristics found

in other common amino acids, including the presence of an ammonium-carboxylate synthon, which acts as a donor or acceptor for hydrogen bonds, as well as the ability to strengthen crystal lattices through the use of non-covalent hydrogen bonds, which are typically more powerful than neutral hydrogen bonds. L-proline in particular is thought of as a restricted, rather stiff amino acid with a penta cyclic ring, which is rare among amino acids but which may provide it an entropic edge over other amino acids in the creation of NBH cocrystals. L-proline has the best solubility among all the amino acids from a natural standpoint, and because of this, it is well recognized as a solubilizing excipient that is employed in pharmaceutical synthesis research. From each of these perspectives, we can forecast the possibility of using L-proline and L-glutamine as cofomers in conjunction with NBH to improve its qualities as well as some novel insight on altering NBH using amino acid zwitterions [13, 14].

With the use of liquid-assisted grinding and solvent evaporation, Nikam *et al.* [10] produced cocrystals of NBH utilizing cofomers such as 4-hydroxy benzoic acid and nicotinamide. Tilborg, Anaëlle, *et al.* [15] highlighted the cocrystal formations containing L-Proline, a zwitterionic amino acid, and naproxen.

The primary goal of this effort is to improve aqueous solubility and comprehend the physicochemical properties of NBH medication. Donor (-NH<sub>2</sub>) and acceptor (-COOH) groups, of amino acids frequently establish hydrogen bonds with hydroxyl groups of NBH. This was done to deal with challenges with the drug's poor water solubility, dissolution, and stability to increase its efficacy.

The morphology and physical properties of nebivolol hydrochloride and the unique cocrystal were characterized using differential thermogram, PXRD, FTIR, and electron beam-focused microscopy techniques.

## MATERIALS AND METHODS


### Materials

Nebivolol hydrochloride (NBH) gift sample received from Global Calcium Pvt. Ltd., Bangalore. Other high purity Chemicals L-proline, L-glutamine, and methanol were procured. Every other resource used in the study was of industrial grade.

### Selection of the cofomer and its proportion

Nebivolol hydrochloride has -OH groups and the -NH group, which are both visible in **Figure 1**. When examining the functional groups of NBH, a cofomer with the group of amide and carboxylic acids may have a chance of forming hydrogen bonds. There are a large number of appropriate conformers accessible for pharmaceutical cocrystal engineering according to GRAS,

a thorough pathway from the literature, however, L-proline and L-glutamine were chosen as two coformers based on prior literature studies [16, 17]. The acidic and basic functional groups of API can establish hydrogen bonds or non-covalent interactions with the coformers. For the current investigation, zwitterionic substances such as L-proline and L-glutamine were used at a 1:1 stoichiometric molar ratio.



**Figure 1.** The 3- hetero supramolecular synthon between (a) NBH and L-proline and (b) NBH and L-glutamine.


### Novel NBH cocrystal preparation by liquid-assisted grinding

NBH (441 mg), L-proline (122 mg), and a few drops of methanol as a solvent were added to a clean mortar and pestle in an equimolar 1:1 stoichiometric ratio. Then the ingredients were mechanically ground for 40 minutes. This mechanical grinding method uses green chemistry, making it environmentally beneficial. The novel cocrystals of NBH were collected and preserved after grinding. The cocrystals at a 1:1 stoichiometric molar ratio of the coformers and API suggested better physicochemical attributes, such as dissolution rate and aqueous solubility.

### Novel NBH cocrystal preparation by slow solvent evaporation

The novel zwitterionic NBH cocrystals were designed employing a solvent evaporation approach with L-glutamine as a coformer. When NBH (500 mg) and L-glutamine (140 mg) are combined in a molar ratio of 1:1, cocrystals are generated. 15 cm<sup>3</sup> of methanol was used to dissolve the NBH, and 5 cm<sup>3</sup> of distilled water were used to dissolve the coformer. After thoroughly dissolving the substance to create a clear solution, both solutions were ultrasonically treated while being agitated. A solution of L-glutamine in water was dropped gradually into a methanol solution containing NBH and placed on the magnetic stirring device, which stirred continuously until the solvent was fully evaporated. To dry, the cocrystals were placed overnight in a glass container with a moisture-removing drying agent. A schematic representation of the synthesis of cocrystals is shown in

**Figure 2.**



**Figure 2.** Schematic representation of synthesis of cocrystals

### Identification methods

#### Powder X-ray diffraction analysis

The X-ray diffraction (XRD) data of synthesized samples and pure form has been recorded using an X-ray diffractometer Si (Lithium) *position-sensitive detector* Copper X-ray source ( $\lambda = 1.5406\text{\AA}$ ). The measurements were taken between angular ranges of 4-40°.

#### Fourier transform infra-red spectroscopy analysis

Fourier Transform Infra-red analysis (FTIR) of NBH and cocrystals was obtained using a Bruker-2 with an attenuated total reflection detector and a DLATGS detector with a spectral resolution of  $2\text{ cm}^{-1}$ . After adding 2 mg of each material to the sample cell, spectra between 4000 and  $500\text{ cm}^{-1}$  were acquired. The data collected was evaluated using Origin software.

#### Differential scanning calorimetry analysis

A differential thermogram was used to examine the materials' melting behavior. Each sample, weighing 1.5-2.5 mg of NBH, cofomers, and unique cocrystals, was scanned using a DSC 823e calorimeter made by the Swiss company Mettler Toledo. Every single sample was placed inside a 40-microliter sealed aluminum pan, with an empty sealed aluminum pan used as a standard. Using nitrogen gas flow at a rate of 20 ml/min, all samples were scanned at a rate of 10 °C per minute between RT and 300 °C.

#### Solubility analysis

The NBH, NBH-P, and NBH-G were dissolved in 10 mL of distilled water and placed in glass vials with caps. The resulting slurries were then stirred orbital shaker running at 100 rpm for 24 hours at room temperature. The quantity of NBH, NBH-P, and NBH-G solubilized was then measured spectrophotometrically at 280 nm using a UV-1900 Series Model (S/N): UV-1900i (A12535780084) after each solution had been filtered through a paper filter.

#### Morphology analysis

The morphology of the NBH and NBH cocrystals (NBH-P and NBH-G) were examined using SEM (SEM; Hitachi S3400, Japan). The particles were mounted on aluminum skewers and covered with gold while under vacuum to prepare them for examination. At various magnifications, the samples were photographed under a microscope.

#### Intrinsic dissolution rate measurement

A USP equipment dissolution tank with 900 cc of phosphate buffer as the dissolving media was used to perform studies on the intrinsic dissolution of API and cocrystals at pH 7.4 to replicate an actual intestinal


environment. The paddle was rotating at a speed of 100 rpm and the water bath temperature was 37 °C. A sample was obtained to determine the concentration at 10, 20, 30, 40, 50, 60, and up to 120 minutes. For each sample, three runs of dissolution test were performed. The concentration was calculated at 280 nm using a UV spectrophotometer.

## RESULTS AND DISCUSSION

NBH, a third-generation beta-blocker drug that has been authorized by the FDA for the treatment of hypertension with a water solubility barrier, is used in the present study as an API to cocrystallize with L-proline and L-glutamine. Using the solvent evaporation method, NBH and L-glutamine were combined with water and methanol as solvents. NBH and L-proline were combined with a few drops of methanol as solvent using the liquid-assisted grinding method. A 1:1 molar ratio [18] of NBH and zwitterionic cofomers is employed to create the required cocrystal.

#### Powder X-ray diffraction analysis

Powder X-ray diffraction (XRD) analysis is utilized to confirm the phase transition and purity of the current cocrystal since it is a practical and sensitive characterization method for crystalline solid-state forms. In their solid states, most medications can be found in crystalline, amorphous polymorph, and solvate forms, among others. The physicochemical characteristics of these forms can also vary greatly [19]. **Figure 3** displays the XRD spectra of the API, cofomers, and unique cocrystals. The crystalline form of the NBH was confirmed by XRD (**Figure 3**), which revealed clear, distinct peaks at  $2\theta = 5.89^\circ, 11.9^\circ, 12.62^\circ, 16.3^\circ, 18.4^\circ, 21.21^\circ, 22.7^\circ, 24.84^\circ, \text{ and } 25.42^\circ$ . The XRD pattern of the cocrystals of NBH-P and NBH-G reveals the emergence of new peaks with higher intensities. The NBH-P cocrystals made using the solvent-aided grinding approach peaked at  $2\theta = 8.8^\circ, 13.3^\circ, 14.8^\circ, 17.43^\circ, 19.3^\circ, 23.1^\circ, \text{ and } 26.5^\circ$ . However, for NBH-G  $2\theta = 6.8^\circ, 11.7^\circ, 16.9^\circ, 17.3^\circ, 19.3^\circ, 23.7^\circ, \text{ and } 24.8^\circ$  cocrystals made using the solvent evaporation approach revealed additional peaks. This confirms the formation of cocrystals [20].



**Figure 3.** Powder XRD pattern of NBH and co-crystals


#### Fourier transform infra-red spectroscopy

FTIR analysis was accepted as a persuasive justification technique in endorsing the formation of zwitterionic cocrytals, for the idea that the frequencies of vibrational patterns linked to the active moieties would be influenced when changes like hydrogen bonding occur in these groups due to the formation of novel crystalline form [14]. **Figure 4** depicts the FTIR spectra of NBH and cocrytals. The FTIR spectra of NBH showed distinctive peaks caused by different functional groups. O-H stretching of alcohol is at  $3185\text{ cm}^{-1}$ , N-H stretching of amine is at  $3376\text{ cm}^{-1}$ , aromatic C-H is at  $2964.85\text{ cm}^{-1}$ , C-C stretch is at  $1498\text{ cm}^{-1}$ , halogen C-X is at  $869\text{ cm}^{-1}$ , and C-F is at  $1141\text{ cm}^{-1}$ , respectively [19]. L-Proline unique peaks were found to be at  $1609$ ,  $2352$ , and  $3053\text{ cm}^{-1}$ , which correspond to the carboxylic acid C-O, N-H, and O-H stretching, respectively [21]. As shown in **Figure 4**, the distinctive O-H stretching peak of the carboxylic acid for L-glutamine was assigned at  $3166\text{ cm}^{-1}$ , and a broad multiple peak for the N-H stretch of the amide was assigned at  $3401\text{ cm}^{-1}$ .

Since non-covalent interaction hydrogen bonding developed in the zwitterionic cocrytal, a change in the IR spectrum between the cocrytal and its related starting components was also noticed. Several IR peaks changed consequently, as shown in **Figure 4**.

The investigation of the spectra reveals a wave number shift from the N-H stretch (Amine)  $3376$  shifted to  $3409\text{ cm}^{-1}$ , the O-H stretch (Alcohol)  $3185$  shifted to  $3172\text{ cm}^{-1}$ , and the  $1609\text{ cm}^{-1}$  C-O stretching of the carboxylic acid of L-Proline shifted to  $1625\text{ cm}^{-1}$ . This shift is indicative of the formation of a hydrogen bond between the NBH and L-Proline. Hydrogen bonding may be seen in the peak in the  $2400\text{--}3400\text{ cm}^{-1}$  stretch range.

The O-H peak of the alcoholic group of NBH was displaced from  $3185$  to  $3177\text{ cm}^{-1}$ , and the -N H peak of L-Glutamine was shifted from  $3401$  to  $3409\text{ cm}^{-1}$ , while the carbonyl group was shifted from  $1681$  to  $1623\text{ cm}^{-1}$ . The change of the frequency that generated due to the formation of hydrogen bonds flanked by the OH group of NBH and Zwitter ionic carboxylic O group of amino acid cofomers O-H---O. This is in agreement with the literature reports [22]. An outline of possible cocrytal structures of NBH-P and NBH-G are shown in **Figures 1a and 1b**, respectively.




**Figure 4.** FTIR Spectra of NBH and cocrytals

#### DSC analysis

It is the most popular quick, practical, and effective approach for analyzing the cocrytal formation between API and cofomer. **Figure 5** depicts the DSC thermograms of NBH, cofomers L-proline, L-glutamine, and new cocrytals NBH-P, NBH-G. NBH and cofomers display an endothermic peak on the DSC curve of their starting materials that may be ascribed to melting at temperatures of  $224\text{ }^{\circ}\text{C}$ ,  $220\text{ }^{\circ}\text{C}$ ,  $194\text{ }^{\circ}\text{C}$ ,  $169\text{ }^{\circ}\text{C}$ , and  $174\text{ }^{\circ}\text{C}$ , respectively. Between the melting points of NBH and the cofomers, the single endothermic peak lies at  $169$  and  $174\text{ }^{\circ}\text{C}$ , respectively. Cocrytals' NBH-P and NBH-G melting points should be attributed to these peaks. The observed melting point of the cocrytals is different from that of the parent drug molecule and the cofomers. These changes indicate the establishment of the cocrytals of NBH-P and NBH-G [23]. Perlovich's research indicates that compared to the initial materials,  $55.3\%$  of cocrytals have an intermediate melting point,  $28.9\%$  have a low melting point, and  $14.5\%$  have a higher endotherm. NBH-P and NBH-G have melting values of  $169\text{ }^{\circ}\text{C}$  and  $174\text{ }^{\circ}\text{C}$ , respectively, which are typical for 1:1 stoichiometric cocrytals. This suggests that the cocrytal melting point

is in the middle of the NBH and the cocrystals melting points. The position and form of endothermic melting peaks in a DSC analysis serve as a depiction of the distinctive character of cocrystals. Crisp and narrow endothermic peaks are seen in novel cocrystals, suggesting a high degree of crystallinity and purity [24].




**Figure 5.** DSC thermograms of NBH and Cocrystals

#### Solubility analysis


Solubility is a fundamental aspect yet it is difficult to overcome since it is one of the primary factors that drives the processes of medication absorption, transportation, metabolism, and excretion. During drug development and design, researchers modify and test the qualities of various drugs [14]. Approximately 100 mg of each NBH, NBH-P, and NBH-G cocrystals were added to 10 ml of distilled water, which was then constantly agitated for 24 hours at room temperature to verify the solubility. The concentration of the pure drug (NBH) was  $847 \pm 18$   $\mu\text{g/ml}$  and the concentration of cocrystals was found to be NBH-P ( $1779 \pm 48$   $\mu\text{g/ml}$ ) and NBH-G ( $1575 \pm 26$   $\mu\text{g/ml}$ ). For the NBH, and cocrystals NBH-P and NBH-G, which demonstrated an increase in water solubility.

#### Scanning electron microscopy analysis


The SEM images for NBH, NBH-P, and NBH-G are shown in **Figures 6a-6c** respectively. The NBH exhibited rectangular morphology as shown in **Figure 6a**. This is in agreement with the literature [21]. Due to agglomeration, a spherical morphology was observed in NBH-P (**Figure 6b**) and rod-like morphology in NBH-G (**Figure 6c**). The SEM images are inconsistent with XRD data.



a)



b)



c)

**Figure 6.** Scanning electron microscopy (SEM) images of (a) NBH, (b) NBH-P, and (c) NBH-G

#### Calibration curve and dissolution studies

The calibration curve yielded a high magnitude correlation value which is equal to 0.9998. The NBH content quantity and the drug release percentage upon dissolution were calculated using the following calibration curve equation:

$$Y = 0.0086 X + 0.0132, \quad (1)$$

X = amount of NBH,

Y = the ratio of the area that was determined for each time point.

Among the NBH ratios of concentration to area at various time points, the equation demonstrates a solid linear connection. The correlation coefficient r value is quite near to one, illustrating the significant link between the concentration and the area ratio [25].

**Figure 7** shows the in vitro dissolution patterns of the cocrystals NBH-P and NBH-G in comparison to those of the pure drug NBH. The zwitterionic NBH cocrystals

showed a greater in vitro dissolution rate. After 60 minutes, pure drug NBH releases 47.26% of its active ingredient, whereas cocrystals release 81.6% (NBH-P) and 79.4% (NBH-G), respectively. The fast rate of prepared cocrystal dissolution can be attributed to the NBH crystallinity changing as a result of potential hydrogen bond interactions with coformers [26].




Figure 7. Dissolution studies of NBH and cocrystals

NBH's undesirable physicochemical attributes frequently prevent them from delivering the therapeutic advantages promised to them. Cocrystals are crystalline substances amalgamated through one of the latest approaches for improving drug physicochemical attributes composed of non-covalent intermolecular interaction between active moiety and coformer in the same crystal lattice in a particular stoichiometric ratio. Amino acids seem to be an excellent choice as a practical companion in this scenario. Amino acids fall within the GRAS category since they are also extremely inexpensive and low in toxicity.

The establishment of a novel phase is demonstrated by the emergence of new peaks that have elevated intensities in the current cocrystals seen during PXRD analysis. PXRD data confirms that the drug changed from its partly crystalline state to a novel crystalline structure in both cocrystals. This distinct phase may be attributed to the formation of cocrystals owing to the hydrogen bond interaction between NBH and a coagent substance.

The FTIR spectrum suggested that there was good interaction between NBH and coformers as evidenced by spectral alterations, such as a small displacement of the NBH-P and NBH-G distinctive peaks. A change in the peaks of NBH and conformers to the O-H peak of the alcoholic group of NBH, the N-H stretch of amine, and C=O stretching, respectively, suggests that hydrogen bonding is exceptionally likely to occur. The frequency shift is caused by the creation of the NBH--O-H---O Carboxylic O group of amino acid coformers, which are flanked by the OH groups of NBH and Zwitterionic

amino acids. This is consistent with the reports in the literature [22]. The findings of this study additionally supported the use of DSC as a tool to complement information gleaned from FTIR and PXRD spectra. On the DSC curve of their starting materials, NBH and coformers show an endothermic peak that may be attributed to melting at temperatures of 224 °C, 220 °C, 194 °C, 169 °C, and 174 °C, respectively. The single endothermic peak for the cocrystals NBH-P and NBH-G is located at 169 and 174 °C, respectively. These modifications show that NBH-P and NBH-G cocrystals have formed.

Comparing the apparent solubility of novel cocrystals to that of pure NBH. The solubility of plain NBH was 847.18 µg/ml, but that of NBH cocrystals was 177.48 and 1575.26 µg/ml, respectively, which is about 2.1-fold and 1.86-fold greater than that of the parent molecule.

Cocrystals NBH-P and NBH-G exhibited spherical and rod-like surface forms, contrasting the flat rectangular surface of pure NBH. This change recommends that the intermolecular hydrogen bonds between the drug and the coformer influence the cocrystals' habits.

The quantity of NBH-P and NBH-G drug release was seen to range between 81.6% and 79.4% during 120 minutes. There was an increase of around 40–50% in the cumulative fraction of drug release. An increase in dissolution rate quickens the pace of drug absorption through the gastrointestinal tract. The approach employed to put the concept of cocrystals into practice was effectively discussed in earlier literature, which might be useful for the process advancement in subsequent research.

## CONCLUSION

The first zwitterionic cocrystal of NBH with L-glutamine and L-proline was magnificently formed in the current study. The evaluations of the prepared cocrystals by XRD, FTIR, DSC, SEM, and dissolution studies all indicated the formation of novel crystal lattices NBH-P and NBH-G. The changes in infrared peaks, XRD 2θ values, melting point in DSC peaks, and surface morphology by SEM all indicated that unique molecular structures were formed as a result of the formation of NBH cocrystals. The peak shift in IR spectra also confirms the establishment of hydrogen bonds flanked by NBH and the coformers. These findings indicate that NBH-P and NBH-G cocrystals may be a prospective agent with improved in vitro dissolution routine, demonstrating the capacity of L-proline and L-glutamine to enhance their properties through the cocrystallization process. As effective cocrystal formers, zwitterionic amino acids may now be used in a wider range of therapeutic applications.

**Acknowledgments:** The authors are thankful to the management of Presidency University, Bengaluru, for providing final assistance through the university seed grant to purchase chemicals (File No: RI & C /Funded project/SI-3, SI-4, dated 08/11/2021). One of the authors (CD) is thankful to MES College of Arts, Commerce and Science, Malleshwaram, Bengaluru, Karnataka, for providing the facilities to carry out the research work. The authors would like to thank I-STEM, the Indian Institute of Science, and Poornayu Research Labs, for providing characterization facilities for PXRD, DSC, SEM, and Dissolution studies.

**Conflict of interest:** None

**Financial support:** None

**Ethics statement:** None

## REFERENCES

- Xu J, Shi Q, Wang Y, Wang Y, Xin J, Cheng J, et al. Recent advances in pharmaceutical cocrystals: a focused review of flavonoid cocrystals. *Molecules*. 2023;28(2):613. doi:10.3390/molecules28020613
- De Souza FZ, De Almeida AC, Ferreira PO, Fernandes RP, Caires FJ. Screening of cofomers for quercetin cocrystals through mechanochemical methods. *Eclét Quím*. 2022;47(1):64-75. doi:10.26850/1678-4618eqj.v47.1.2022.p64-75
- Basavoju S, Boström D, Velaga SP. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. *Pharm Res*. 2008;25(3):530-41. doi:10.1007/s11095-007-9394-1
- Sarkar A, Rohani S. Molecular salts and co-crystals of mirtazapine with promising physicochemical properties. *J Pharm Biomed Anal*. 2015;110:93-9. doi:10.1016/j.jpba.2015.03.003
- Dhondale MR, Thakor P, Nambiar AG, Singh M, Agrawal AK, Shastri NR, et al. Co-Crystallization approach to enhance the stability of moisture-sensitive drugs. *Pharmaceutics*. 2023;15(1):189. doi:10.3390/pharmaceutics15010189
- Aghara M, Dudhat K. Solubility and dissolution enhancement of luliconazole by a cocrystal engineering technique with different cofomers. *J Pharm Innov*. 2023;18(7):1-2. doi:10.1007/s12247-023-09751-4
- Madanayake SN, Manipura A, Thakuria R, Adassooriya NM. Opportunities and challenges in mechanochemical cocrystallization toward scaled-up pharmaceutical manufacturing. *Org Process Res Dev*. 2023;27(3):409-22. doi:10.1021/acs.oprd.2c00314
- Lu J, Li YP, Wang J, Li Z, Rohani S, Ching CB. Pharmaceutical cocrystals: a comparison of sulfamerazine with sulfamethazine. *J Cryst Growth*. 2011;335(1):110-4. doi:10.1016/j.jcrysgro.2011.09.032
- Chiou WL, Chen SJ, Athanikar N. Enhancement of dissolution rates of poorly water-soluble drugs by crystallization in aqueous surfactant solutions I: sulfathiazole, prednisone, and chloramphenicol. *J Pharm Sci*. 1976;65(11):1702-4. doi:10.1002/jps.2600651137
- Nikam VJ, Patil SB. Pharmaceutical cocrystals of nebivolol hydrochloride with enhanced solubility. *J Cryst Growth*. 2020;534:125488. doi:10.1016/j.jcrysgro.2020.125488
- Kasten G, Löbmann K, Grohganz H, Rades T. Co-former selection for co-amorphous drug-amino acid formulations. *Int J Pharm*. 2019;557:366-73. doi:10.1016/j.ijpharm.2018.12.036
- Tilborg A, Norberg B, Wouters J. Pharmaceutical salts and cocrystals involving amino acids: a brief structural overview of the state-of-art. *Eur J Med Chem*. 2014;74:411-26. doi:10.1016/j.ejmech.2013.11.045
- Vemuri VD, Lankalapalli S. Rosuvastatin cocrystals: an attempt to modulate physicochemical parameters. *Future J Pharm Sci*. 2021;7(1):64. doi:10.1186/s43094-021-00213-7
- Fayaz TK, Palanisamy V, Sanphui P, Chernyshev V. Multicomponent solid forms of antibiotic cephalixin towards improved chemical stability. *CrystEngComm*. 2023;25(8):1252-62. doi:10.1039/D2CE01283A
- Tilborg A, Springuel G, Norberg B, Wouters J, Leysens T. On the influence of using a zwitterionic cofomer for cocrystallization: structural focus on naproxen-proline cocrystals. *CrystEngComm*. 2013;15(17):3341-50. doi:10.1039/c3ce40084k
- Deng Y, Liu S, Jiang Y, Martins IC, Rades T. Recent advances in co-former screening and formation prediction of multicomponent solid forms of low molecular weight drugs. *Pharmaceutics*. 2023;15(9):2174. doi:10.3390/pharmaceutics15092174
- Wang LY, Yu YM, Jiang FB, Li YT, Wu ZY, Yan CW. The first zwitterionic cocrystal of indomethacin with amino acid showing optimized physicochemical properties as well as accelerated absorption and slowed elimination in vivo. *N J Chem*. 2020;44(10):3930-9. doi:10.1039/C9NJ06180K





18. Nugrahani I, Utami D, Ibrahim S, Nugraha YP, Uekusa H. Zwitterionic cocrystal of diclofenac and L-proline: structure determination, solubility, kinetics of cocrystallization, and stability study. *Eur J Pharm Sci.* 2018;117:168-76. doi:10.1016/j.ejps.2018.02.020
19. Nugrahani I, Jessica MA. Amino acids as the potential co-former for co-crystal development: a review. *Molecules.* 2021;26(11):3279. doi:10.3390/molecules26113279
20. Ghafari R, Jahangiri A, Shayanfar A, Emami S. Solid-state characterization of ibuprofen-isonicotinamide cocrystals prepared by electro-spraying and solvent evaporation. *Ther Deliv.* 2023;14(2):121-38. doi:10.4155/tde-2022-0072
21. Trivedi HR, Siriah TM, Puranik PK. Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl. *Braz J Pharm Sci.* 2020;56:e18070. doi:10.1590/s2175-97902019000418070
22. He H, Huang Y, Zhang Q, Wang JR, Mei X. Zwitterionic cocrystals of flavonoids and proline: solid-state characterization, pharmaceutical properties, and pharmacokinetic performance. *Cryst Growth Des.* 2016;16(4):2348-56. doi:10.1021/acs.cgd.6b00142
23. Omori M, Yamamoto H, Matsui F, Sugano K. Dissolution profiles of carbamazepine cocrystals with Cis-trans isomeric cofomers. *Pharm Res.* 2023;40(2):579-91. doi:10.1007/s11095-022-03209-x
24. Perlovich GL. Thermodynamic characteristics of cocrystal formation and melting points for rational design of pharmaceutical two-component systems. *CrystEngComm.* 2015;17(37):7019-28. doi:10.1039/C5CE00992H
25. Younes H, Adib SS, Ibrahim MI, Shalash AA. Dissolution testing and content uniformity analysis for metformin tablets using vildagliptin as an internal standard. *J Hunan Univ Nat Sci.* 2023;50(1):1-9. doi:10.55463/issn.1674-2974.50.1.1
26. Bhalekar M, Pradhan SB. Scientific cofomer screening, preparation and evaluation of fenofibrate tartaric acid cocrystal. *J Drug Deliv Ther.* 2019;9(4):406-10. doi:10.22270/jddt.v9i4.3199